Immunology companies study and manipulate the immune system to develop therapies, diagnostics and research tools. The field plays a central role in areas such as cancer, infectious disease, autoimmune disorders and vaccine development.
This category includes companies working on:
Browse 182 UK immunology companies below.
Intestinal barrier repair therapies for inflammatory bowel disease
Thelior Bio is a University of Oxford spin-out developing therapies for inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Its research focuses on restoring the intestinal epithelial barrier, addressing impaired tissue repair associated with chronic inflammation. The company draws on…
T cell immunotherapies for infectious disease, cancer and autoimmunity
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific T cell immunotherapies for chronic infectious diseases, autoimmune conditions, and cancer. Its pipeline is built on four proprietary viral vector and synthetic immunotherapy platforms and includes clinical candidates…
Off-the-shelf cancer immunotherapies targeting solid tumours
Scancell is a clinical-stage biotech developing active immunotherapies and antibody-based therapeutics for cancer. Its pipeline spans DNA cancer vaccines, peptide immunotherapies and tumour-specific monoclonal antibodies targeting glycans expressed on cancer cells. Lead programmes iSCIB1+ and Modi-1 are in Phase 2…
Amniotic membrane biotherapies for ocular surface repair and regeneration
NuVision Biotherapies is a regenerative medicine company developing tissue-based biotherapies for ocular surface disease and trauma. Its proprietary processing technology manufactures dry-preserved human amniotic membrane grafts that retain the membrane's natural barrier and healing properties whilst enabling ambient…
Targeted antibody therapeutics for cancer and autoimmune disease
Medannex is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics targeting annexin-A1, a protein implicated in cancer progression, autoimmunity, and inflammation. Its lead asset, MDX-124, is the first therapeutic antibody to target annexin-A1 and is currently being evaluated in the…
Specialist immunology CRO for preclinical biotherapeutic drug discovery
RoukenBio is a specialist contract research organisation providing preclinical immunology services to biopharmaceutical companies worldwide. Its team offers cell-based bioassay development, functional characterisation of antibody therapeutics and complex biologics, cell line engineering, and CMC-quality potency assay…
Biologic therapies for autoinflammatory and autoimmune diseases
Kiniksa Pharmaceuticals International is a commercial-stage biopharmaceutical company focused on acquiring, developing and commercialising medicines for autoinflammatory and autoimmune diseases with significant unmet need. Its approved product, rilonacept, is an IL-1 inhibitor indicated for recurrent pericarditis. The…
Immunology CRO for immuno-oncology, autoimmunity and inflammation
Celentyx is a contract research organisation providing bespoke assay services in human immunology to pharmaceutical and biotechnology clients. Operating from sites in Birmingham and Oxford, the company uses primary human cells and tissues from healthy donors and patients to support drug discovery across…
Oncolytic viral therapies engineered for intravenous cancer treatment
Theolytics is a clinical-stage biotechnology company developing oncolytic viral therapies for cancer. Its phenotypic screening platform enables the discovery and development of adenovirus-based candidates optimised for intravenous delivery and specific patient populations. The lead programme, THEO-260, entered Phase…
Oncolytic vaccinia virus platform targeting refractory solid tumours
VacV Biotherapeutics is a cancer immunotherapy company developing engineered oncolytic Vaccinia virus-based therapeutics for the treatment of solid tumours. Spun out of Barts Cancer Institute and Queen Mary University of London, the company's platform uses a modified Vaccinia virus to simultaneously destroy tumour…
Pharma-university venture funding early-stage translational research
Apollo Therapeutics is a biopharma company advancing therapeutic programmes derived from research at partner universities including Cambridge, Imperial College London, UCL, King's College London, and the Institute of Cancer Research. Originally a joint venture between three universities and AstraZeneca, GSK, and…
Multispecific immune cell engagers targeting gamma delta T cells
Cytospire Therapeutics is developing multispecific engager antibodies designed to enhance and direct the activity of gamma delta T cells for the treatment of cancer and autoimmune disease. The company emerged from stealth in 2024, backed by Abingworth, 4BIO Capital and LifeArc Ventures. Its platform targets both…
Probiotic microbiome platform for skin health and dermatological conditions
SkinBioTherapeutics is a biotechnology company developing microbiome-based technologies for skin health. Its proprietary platform harnesses lysates derived from probiotic bacteria to improve skin barrier function, reduce infection risk, and support wound healing. Programmes target cosmetic skincare, psoriasis, eczema,…
Engineered macrophage cell therapy for inflammatory and fibrotic disease
Resolution Therapeutics is a clinical-stage biotech developing regenerative macrophage therapies for inflammatory and fibrotic diseases. Its platform harnesses the tissue-repairing properties of macrophages, engineering them to deliver anti-fibrotic and anti-inflammatory effects at sites of organ damage. The lead…
Novel mRNA technology platform for safer, faster vaccines
CamMed Therapeutics (Cambridge Medixine Ltd) is a preclinical biotechnology company developing a novel mRNA technology platform for vaccines and therapeutics. Inspired by natural biological phenomena, its engineered RNA molecules are designed to deliver safer, easier and faster medicines to the clinic while reducing…
TCR-based bispecific therapeutics for cancer and autoimmune disease
T-Therapeutics is a biotechnology company developing T cell receptor-based therapeutics for cancer and autoimmune disease. Using a humanised TCR mouse platform to generate high-affinity, antigen-specific human T cell receptors, the company engineers bispecific molecules that redirect a patient's own T cells to…
VNAR antibody shuttles for brain-targeted biologic therapies
Ossianix is a biopharmaceutical company developing single-domain VNAR antibody platforms for targeted delivery of therapeutics across the blood-brain barrier. Its TXP1 shuttle binds transferrin receptor 1 to transport antibody-based medicines into the central nervous system. The company engineers antibody fusions and…
Blood group reference testing, antibody reagents and assay development
IBGRL comprises NHS Blood and Transplant laboratories in Filton, Bristol, providing specialist blood group reference testing, transfusion research and biological reagents. Its red cell reference team investigates complex antibody and antigen cases, while IBGRL Research Products supplies monoclonal antibodies and…
Purified allergens, test kits, and environmental allergen testing
InBio is a biotechnology company specialising in the manufacture of highly purified allergens, antibodies, and immunoassay kits for allergy research, diagnostics, and environmental monitoring. Its Cardiff laboratory provides contract allergen testing services for environmental and food allergen exposure assessment,…
Preclinical therapeutic company targeting tissue fibrosis in allergic asthma
Fibraxis is a preclinical-stage biotechnology company developing a therapeutic for allergic asthma that targets tissue fibrosis in the lung. Spun out of Aston University and supported by SPARK The Midlands, the company builds on research into pericytes, the mesenchymal cells implicated in airway scarring and…